摘要
目的探讨肺癌脑转移患者采用靶向药物治疗联合放化疗的临床效果及安全性。方法本研究选取2020年6月-2021年6月大庆龙南医院接收的96例肺癌脑转移患者作为研究对象,以奇偶数方式分为常规组和联合组,每组48例,分别应用全脑同步放疗结合同步化疗治疗和放化疗联合靶向药物治疗,分析两组治疗效果。结果联合组近期疗效(83.33%)高于常规组(58.33%),差异有统计学意义(χ^(2)=7.261,P=0.007);联合组生存时间相较于常规组更长,差异有统计学意义(t=9.904,P<0.001);联合组1年生存率相较于常规组更高,差异有统计学意义(χ^(2)=4.174,P=0.041);联合组1、4、10周生存质量分数较常规组更高,差异有统计学意义(P<0.05);联合组不良反应发生率(6.25%)低于常规组(10.42%),但差异无统计学意义(χ^(2)=0.136,P=0.712)。结论肺癌脑转移患者采用靶向药物治疗联合同步放化疗治疗后效果显著,能够有效延长患者生存时间,提升生存质量。
Objective To investigate the clinical effect and safety of targeted drug therapy combined with radiochemo⁃therapy in patients with brain metastases from lung cancer.Methods In this study,96 patients with lung cancer brain metastasis received in Daqing Longnan Hospital from June 2020 to June 2021 were selected as the research objects,and divided into the conventional group and the combined group by odd and even way,with 48 patients in each group.The treatment effects of the two groups were analyzed respectively by using synchronous whole-brain radio⁃therapy combined with synchronous chemotherapy and radiotherapy combined with targeted drugs.Results The short-term efficacy of the combination group(83.33%)was higher than that of the conventional group(58.33%),and the difference was statistically significant(χ^(2)=7.261,P=0.007);the survival time of the combined group was longer than that of the conventional group,and the difference was statistically significant(t=9.904,P<0.001),the 1-year survival rate of the combined group was higher than that of the conventional group,and the difference was statisti⁃cally significant(χ^(2)=4.174,P=0.041);the quality of life score at week 1,4 and 10 in combined group was higher than that in conventional group,and the difference was statistically significant(P<0.05).The incidence of adverse reac⁃tions in combination group(6.25%)was lower than that in conventional group(10.42%),but the difference was not statistically significant(χ^(2)=0.136,P=0.712).Conclusion Targeted drug therapy combined with concurrent chemoradiotherapy in patients with brain metastases from lung cancer has a significant effect,which can effectively prolong the survival time of patients and improve the quality of life.
作者
李雪
LI Xue(Department of Medical Oncology,Daqing Longnan Hospital(The Fifth Affiliated Hospital of Qiqihar Medical Col-lege),Daqing,Heilongjiang Province,163000 China)
出处
《系统医学》
2022年第12期183-186,共4页
Systems Medicine
关键词
肺癌脑转移
靶向治疗
放化疗
近期疗效
生存时间
Brain metastases from lung cancer
Targeted therapy
Chemoradiotherapy
Short-term efficacy
Survival time
